Remove Small Molecule Remove Therapies Remove Virus
article thumbnail

Looking beyond traditional oncogenic pathways to break cancer resistance

Drug Target Review

Most targeted cancer therapies used today operate by inhibiting targets along well-known oncogenic signalling cascades. The reactivation of oncogenic signalling upstream or downstream of the driving oncogene is a well-studied source of resistance to targeted cancer therapies.

article thumbnail

Targeting a human protein may stop Ebola virus in its tracks

The Pharma Data

To treat Ebola virus infections, researchers are taking a close look at a key piece of the virus: polymerase. Polymerase is a viral protein that directs how Ebola virus replicates its genome as it infects new hosts. Drugs that target polymerase could potentially treat Ebola virus infections and save lives.

Virus 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Codon Digest: Bacteria Resist Every Virus

Codon

Signal Transduction and Targeted Therapy. Marine biofilm engineered to produce current in response to small molecules. Molecular Therapy. Gene Therapy. From a genome-wide screen of RNAi molecules against SARS-CoV-2 to a validated broad-spectrum and potent prophylaxis. How to build a virus-proof cell.

Virus 52
article thumbnail

mRNA Cancer Vaccines and Therapies: An Overview

Advarra

The applications of mRNA-based therapies in cancer research represent one of the next groundbreaking steps toward improved cancer treatments. Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials.

Vaccine 52
article thumbnail

Navigating the Challenges in Clinical Research for Hepatitis C Therapies

Vial

Hepatitis C virus (HCV) infection is a global health problem with complications that place a significant economic burden on national health systems. The Food and Drug Administration (FDA) approved and recommended dozens of small-molecule drugs. On top of this, treated individuals are susceptible to reinfection.

article thumbnail

Selva Therapeutics Announces First Dosing in Phase 1 Clinical Study of SLV213, a Potential Oral Treatment for COVID-19

The Pharma Data

As an orally bioavailable small molecule with broad antiviral activity, SLV213 could be a valuable treatment to meet today’s urgent need to fight COVID-19 as well other life-threatening infectious diseases, such as Chagas disease, Ebola virus disease, and Nipah virus infection.”. About SLV213.

article thumbnail

Novel prophylactic nasal spray reduced COVID-19 replication by 96% in animal studies

The Pharma Data

The product, known as INNA-051, is a synthetic small molecule therapy, self-administered once or twice weekly with an almost immediate effect. Individuals exposed to the virus would most likely rapidly eliminate it, with the treatment ensuring that the disease does not progress beyond mild symptoms.